Showing results (331-340 of 407) with videos related to

Sort By:
Pageof 41
Clinical and Experimental Rheumatology|March 3, 2022
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partnersLuca Iaccarino, Rosaria Talarico, Emanuele Bozzalla-Cassione, et al.
American Journal of Respiratory and Critical Care Medicine|September 3, 2014
Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosisMike O Becker, Angela Kill, Marissa Kutsche, et al.
Annals of the Rheumatic Diseases|January 16, 2021
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trialRené Westhovens, William F C Rigby, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases|May 15, 2020
Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trialClaudia Kedor, Joachim Listing, Jan Zernicke, et al.
Scientific Reports|January 14, 2025
Proteomic, metabolomic and lipidomic profiles in community acquired pneumonia for differentiating viral and bacterial infectionsSamuel Rischke, Robert Gurke, Ann-Sophie Zielbauer, et al.
Arthritis Research & Therapy|March 8, 2008
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA studyAntonio Naranjo, Tuulikki Sokka, Miguel A Descalzo, et al.
Annals of the Rheumatic Diseases|February 4, 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, et al.
Rheumatology (Oxford, England)|February 17, 2024
The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trialsKaoru Takase-Minegishi, Stefan Böhringer, Jackie L Nam, et al.
The Journal of Rheumatology|August 1, 2023
Proceedings of the Collaborative Research Network Meeting at the GRAPPA 2022 Annual MeetingBeverly Cheok Kuan Ng, Deepak Jadon, Frank Behrens, et al.
The Journal of Rheumatology|April 3, 2008
Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)Christian E Antoni, Arthur Kavanaugh, Désirée van der Heijde, et al.
Pageof 41